Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).

Papillomaviruses are responsible for almost all cervical cancers. In France, there are more than 3000 new cases of cervical cancer each year and nearly 1000 deaths. One of the ways to prevent this cancer is screening by PCR on cervical sample for which national coverage rate remains very insufficient (\<60%). The invasive and uncomfortable nature of cervical sampling has been identified as a major obstacle to screening. In this context, an alternative sample, such as the first-void urine, seems to be judicious. Nevertheless, some studies have shown a lack of sensitivity of the HPV PCR test on

Trial Details

NCT ID
NCT06254846
Phase
NA
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Urine sample, 1st stream
  • Cervico-vaginal swab
Locations (sample)
  • Saint-Etienne, France|45.43389,4.39

Key Eligibility Criteria

  • Age between 30 and 65
  • Consulting in the Gynecology-Obstetrics department for primary cervical cancer screening
  • Patient affiliated or entitled to a social security regimen
  • Patient who has received information about the study and expressed non-opposition

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →